register

News & Trends - Biotechnology

Carina Biotech collaborates to advance CAR-T therapy in advanced bowel cancer

Health Industry Hub | November 15, 2021 |
[Total: 2    Average: 4.5/5]

Biotech News: Carina Biotech recently announced that it has raised $5.4 million to initiate a clinical trial for the treatment of advanced colorectal (bowel) cancer with the company’s lead LGR5-targeted CAR-T program.

Singapore-based CellVec will manufacture clinical-grade lentivirus – the first critical step in making LGR5 CAR-T cells for a first-in-human clinical trial for advanced bowel cancer patients in late 2022.

Professor Simon Barry, CarinaBiotech’s Vice President of Cell Therapy Manufacturing, said “We are delighted to be working with CellVec because of their outstanding track record and expertise. Their flexibility and willingness to incorporate Carina’s proprietary manufacturing process was an important consideration in the selection of CellVec as our service provider.”

Dr Ang Peng Tiam, Chairman of CellVec and Medical Director of Parkway Cancer Centre, commented “The partnership with Carina Biotech marks a significant milestone for us to facilitate the furtherance of gene therapies. We look forward to supporting Carina in the successful development of its LGR5 CAR-T cells.”

Carina’s LGR5 CAR-T cells are targeted at LGR5, a cancer stem cell marker that is highly expressed on colorectal cancer (and other cancers). Colorectal (bowel) cancer is the deadliest cancer for Australians aged 25-34 and Australia’s second deadliest cancer overall. Young-onset colorectal cancer is often diagnosed at later stages, which have a much poorer prognosis.

Carina’s pre-clinical studies of the LGR5-targeted CAR-T cell have shown highly promising results with complete tumour regression and no tumour recurrence. They have also demonstrated impressive tumour access and prolonged CAR-T cell survival.

Carina Biotech CEO, Dr Deborah Rathjen, said “We are continuing to see impressive results with our LGR5 CAR-T cell in pre-clinical testing. After our recent successful capital raise and welcoming new impact investors to our company, we are on track for a pre-IND submission in Q2 of 2022 and an IND submission to the FDA in the second half of 2022. These are important milestones towards the initiation of a Phase I/II clinical trial in patients with advanced colorectal cancer.”

There are two CAR-T therapies available in Australia for blood cancers. Novartis’ Kymriah and Kite Pharma’s Yescarta are publicly funded, with its manufacturing facilities in the Peter MacCallum Cancer Centre in Melbourne and Royal Brisbane and Women’s Hospital in Brisbane.


Human Resources

Human Resource Management - BMS leader shares her personal journey and company's commitment to national reconciliation movement

BMS leader shares personal journey and company’s commitment to national reconciliation movement

Health Industry Hub | December 3, 2021 |

Human Resources: Fostering a future of healing and reconciliation requires all Australians to truthfully and respectfully acknowledge the past.  The […]

More


News & Trends - Pharmaceuticals

Pharma News - Industry welcomes landmark Bill in boosting patient access to novel medicines while protecting from medicine shortages

Industry welcomes landmark Bill in boosting patient access to novel medicines while protecting from medicine shortages

Health Industry Hub | December 3, 2021 |

Pharma News: Australians will see improved access to new and innovative medicines, vaccines and treatments while being better protected against […]

More


News & Trends - Pharmaceuticals

Pharma News -

Pharma industry thanks Minister Hunt for his leadership and partnership

Health Industry Hub | December 3, 2021 |

Pharma News: Medicines Australia wishes to thank the Hon Greg Hunt MP for his service to Australian patients and the […]

More


News & Trends - Medical Technology

MedTech News - Johnson & Johnson backs COVID-19 response for indigenous communities

Johnson & Johnson backs COVID-19 response for indigenous communities

Health Industry Hub | December 3, 2021 |

MedTech News: Johnson & Johnson Family of Companies in Australia is supporting Aboriginal communities in the Northern Territory to protect […]

More